Small Molecule Combo Extends Mouse Lifespan and Improves Neurological Function
RepSox and tranylcypromine combination improved neurological markers and increased maximum lifespan in aging female mice.
Summary
Researchers tested a combination of two small molecules, RepSox and tranylcypromine, in aging female C3H mice. The treatment improved neurological function, reduced skeletal deformities, and maintained better fur quality in older mice. In younger mice followed for survival, the combination significantly increased maximum lifespan compared to controls. The molecules target cellular reprogramming pathways that may reverse aging processes. While promising, the study was limited to one mouse strain and showed some adverse liver effects, requiring further research before human applications.
Detailed Summary
This study investigated whether combining two small molecules could slow aging and extend lifespan in mice. Researchers used RepSox (5 mg/kg) and tranylcypromine (3 mg/kg), compounds that target cellular reprogramming pathways, administered every 72 hours for 30 days to female C3H mice.
The study included two groups: "old" mice (16-20 months) and "senior" mice (10-13 months). In the older group, treated mice showed remarkable improvements in age-related decline. Only 20% of treated mice developed spinal deformities compared to 60% of controls (p<0.01). Treated mice maintained stable fur density while 15-30% of control animals experienced fur loss within 30 days (p<0.05). Neurological assessments revealed enhanced brain function in treated animals.
The younger "senior" group was followed for survival outcomes. While overall survival curves weren't significantly different, maximum lifespan increased significantly in treated mice (p=0.039, Gao-Allison test). Treated animals showed a mortality plateau after month seven, while deaths continued in controls. Weight loss was also slower in treated mice (0.011 g/day vs 0.017 g/day in controls, p<0.05).
Histological analysis revealed increased cortical angiogenesis (blood vessel formation) in treated mice's brains, suggesting improved brain health. However, some adverse changes were noted in liver and brain tissue, indicating the treatment isn't without risks. The researchers observed localized adaptive changes rather than major toxic effects.
These findings suggest that targeting partial cellular reprogramming pathways with specific small molecule combinations may offer therapeutic potential for age-related decline, though safety profiles need further investigation before clinical translation.
Key Findings
- Spinal deformities reduced from 60% in controls to 20% in treated mice (p<0.01)
- Treated mice maintained stable fur density while 15-30% of controls experienced fur loss (p<0.05)
- Maximum lifespan significantly increased in treated vs control mice (p=0.039, Gao-Allison test)
- Weight loss slowed in treated mice: 0.011 g/day vs 0.017 g/day in controls (p<0.05)
- Enhanced neurological status and increased cortical angiogenesis in treated animals
- Mortality plateau observed in treated mice after month seven while deaths continued in controls
- Some adverse histological changes noted in liver and brain tissue of treated mice
Methodology
Randomized controlled study with 42 female C3H mice divided into "old" (16-20 months, n=10) and "senior" (10-13 months, n=11) groups. Mice received intraperitoneal injections of RepSox (5mg/kg) and tranylcypromine (3mg/kg) or DMSO control every 72 hours for 30 days. Statistical analysis included Mann-Whitney tests, mixed-effects linear regression, Kaplan-Meier survival analysis, and Gao-Allison test for maximum longevity.
Study Limitations
Study limited to female C3H mice only, limiting generalizability across sexes and strains. Some adverse histological changes observed in liver and brain tissue raise safety concerns. The study lacked mechanistic analysis of how the compounds work. Authors noted no specific funding, and some authors are affiliated with Longaevus Technologies LTD, a potential commercial interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.